Other KEI comments on NIH licenses are found here: /nih-licenses
Perhaps start with these two:
- Exclusive agreements between Federal agencies and Bristol-Myers Squibb Co. for drug development is the public interest protected? : hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, first session, Washington, DC, July 29, 1991. Published in 1992, by G.P.O., Serial No. 102-35.
-
Susannah Markandya and James Love, Timeline of Paclitaxel disputes, CPTech, 8/23/2001
http://www.cptech.org/ip/health/taxol/taxol-timeline2001.html - CPTech’s page on taxol; http://www.cptech.org/ip/health/taxol/
[Congressional Record Volume 143, Number 148 (Wednesday, October 29, 1997)] [Extensions of Remarks] [Pages E2120-E2121] From the Congressional Record Online through the Government Publishing Office [www.gpo.gov], LOOK OUT CONSUMERS: PHARMACEUTICAL RIP-OFF BEING PROPOSED, HON. FORTNEY PETE STARK. https://www.gpo.gov/fdsys/pkg/CREC-1997-10-29/html/CREC-1997-10-29-pt1-PgE2120-2.htm
GAO REPORT NUMBER: GAO-03-829
ACCOUNT NUMBER: A07075
TITLE: Technology Transfer: NIH-Private Sector Partnership in the Development of Taxol
DATE: 06/04/2003
https://www.gpo.gov/fdsys/pkg/GAOREPORTS-GAO-03-829/html/GAOREPORTS-GAO-03-829.htm
[Senate Hearing 105-524] [From the U.S. Government Printing Office], S. Hrg. 105-524, LEGISLATIVE PROPOSAL TO INCREASE FUNDING FOR MEDICAL RESEARCH, HEARING before a SUBCOMMITTEE OF THE COMMITTEE ON APPROPRIATIONS UNITED STATES SENATE, ISBN 0-16-057151-0. https://www.gpo.gov/fdsys/pkg/CHRG-105shrg46160/html/CHRG-105shrg46160.htm